May 8, 2023 09:00 AM EDT
Deals
Bioregnum
R&D

When is a pre­clin­i­cal drug worth a moth­er lode of cash? This top 20 list of­fers a few an­swers

When Ver­tex is in­tent on a tar­get, the ex­ecs are known to splash out big time for ex­per­i­men­tal prod­ucts.

That gung-ho spir­it was on full …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Sion­na and Odyssey end JPM week with IPO fil­ings

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times